Genomics is yielding a plethora of gene sequences for testing as potential drug targets. But virtually no one in the industry talks about a critical bottleneck in going from gene sequence to drug discovery: the frequent difficulty in producing enough protein for testing.

One company addressing the protein problem is Gryphon Sciences, which has developed chemical synthesis technology as an alternative to recombinant techniques to address the bottleneck.